Immunomodulatory Supplements for B Cell and Autoantibody Regulation
Context. Tissue-specific IgM autoantibody persistence in long COVID — driven by ongoing extrafollicular B cell activation (Tatai et al. 2026) — provides mechanistic rationale for supplements that modulate BCR signaling, NF-\(\kappa\)B activation, and immune tolerance. None of the following supplements have been tested for autoantibody reduction in ME/CFS; evidence is from in vitro studies, animal models, and other autoimmune conditions.
(Certainty: 0.25.) Quercetin is a bioflavonoid that inhibits SYK and BTK phosphorylation — key BCR signaling kinases — and suppresses extrafollicular IgM plasmablast differentiation in vitro. By partially reducing BCR signal intensity, quercetin could lower the threshold for autoreactive B cell activation without the immunosuppression of pharmaceutical BTK inhibitors.
Evidence level: In vitro mechanistic data only; no human autoantibody-reduction studies. Mast-cell-stabilising, antioxidant, and anti-inflammatory effects are better characterized. Typical dose: 500 mg twice daily; quercetin phytosomal formulations improve bioavailability.
Limitations: In vitro BCR inhibition may not translate to in vivo autoantibody reduction. Quercetin’s effect size on autoantibody titers is unknown. Not tested in ME/CFS autoantibody cohorts. (Tatai et al. 2026).
(Certainty: 0.20.) Curcumin inhibits NF-\(\kappa\)B, a transcription factor required for B cell activation and extrafollicular plasmablast differentiation. Phytosomal curcumin formulations achieve plasma levels sufficient for NF-\(\kappa\)B inhibition in vivo. Reducing the NF-\(\kappa\)B-driven inflammatory milieu could indirectly reduce the drive for extrafollicular B cell activation.
Evidence level: In vitro and animal model data (reduced autoantibodies in lupus-prone mice). No human autoantibody-reduction data. Anti-inflammatory effects are better documented. Typical dose: 500 mg phytosomal curcumin twice daily.
Limitations: Curcumin’s autoantibody effects in humans are unknown. Effect size, if any, is likely small. Bioavailability remains a challenge despite formulation advances. Not tested in ME/CFS. (Tatai et al. 2026).
(Certainty: 0.20.) BCR signaling intensity depends on lipid raft composition in the B cell membrane. Omega-3 fatty acids (EPA/DHA) incorporate into membrane phospholipids, increase membrane fluidity, and alter lipid raft composition — potentially reducing BCR signal intensity. Omega-3s also have anti-inflammatory effects via resolvin and protectin production.
Evidence level: Omega-3 supplementation reduces disease activity in rheumatoid arthritis and SLE; B cell effects are inferred from lipid raft biology, not directly demonstrated in human autoantibody studies. Typical dose: EPA+DHA 2–3 g daily.
Limitations: The lipid-raft-to-autoantibody pathway is mechanistic reasoning with no human validation. Effect size on autoantibody titers is unknown and likely small. Not tested in ME/CFS. (Tatai et al. 2026).